Wealth of companion Dx approvals pushes personalized medicine forward; Terumo expanding Michigan headquarters;

@FierceMedDev: The WHO is vetting two circumcision devices designed to slow the spread of HIV in Africa. Story | Follow @FierceMedDev

 @MarkHFierce: Terumo seeks merger deal with Olympus. Will Olympus say yes? More | Follow @MarkHFierce

 @DamianFierce: Despite taking a loss in Q2, Sequenom is forging ahead with its Down syndrome Dx. News | Follow @DamianFierce

> The increased development and approval of companion diagnostics is accelerating the growth of personalized medicine, Chemical & Engineering News reports. Story

> Terumo Cardiovascular Systems has gained a 12-year tax abatement for $4.9 million in capital investment to its headquarters in Scio Township in Michigan. Story

> Aethlon Medical, a maker of therapeutic filtration devices to treat infectious disease and cancer, among other things, has appointed veteran corporate executives Thomas V. Wornham and Philip A. Ward to its board of directors. Release

> BioMed has signed a deal with lab-supply company VWR International to get its InTray and InPouch disease diagnostics into laboratories around the world. More

> Retractable Technologies is launching the VanishPoint blood collection set, a next-generation blood collection device for diagnostic use. Release

Biotech News

 @FierceBiotech: Covance takes a $12.7M loss in Q2. More | Follow @FierceBiotech

 @JohnCFierce: A majority of FDA experts vote for approval of ThromboGenics' eye drug ocriplasmin. Post-OK study would be "nice." Report | Follow @JohnCFierce

 @RyanMFierce: EU approval of Vertex's Kalydeco in cystic fibrosis comes 7 months after FDA stamp. Release | Follow @RyanMFierce

> ThromboGenics wins FDA panel nod for eye drug. News

> Analysts: Ailing Elan casts buyout bait for Biogen Idec. Report

> Buzz: HGS passed up $7B Amgen bid back in the day. Story

> FDA OKs Amarin's blockbuster heart drug contender AMR101. Article

> FDA green-lights Horizon Pharma's Rayos. More

Pharma News

 @FiercePharma: EU OKs Vertex cystic fibrosis drug Kalydeco. News | Follow @FiercePharma

 @EricPFierce: Judge says no to delaying GSK's buyout of Human Genome Sciences. More | Follow @EricPFierce

> Amarin prepared for aggressive launch of billion-dollar fish oil. Story

> Merck earnings down, but strength surprises Wall Street. More

And Finally... Precipio Diagnostics, a Connecticut firm, has a novel way of getting a leg up in cancer Dx. The company struck a deal with Yale University in which it pays 42 of the school's top pathologists on a case-by-case basis. Precipio plans to expand its caseload, possibly inking similar deals with other universities. Report